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Abstract
Microsatellite expansions cause a number of dominantly-inherited neurological diseases. Expansions in coding-regions
cause protein gain-of-function effects, while non-coding expansions produce toxic RNAs that alter RNA splicing activities of
MBNL and CELF proteins. Bi-directional expression of the spinocerebellar ataxia type 8 (SCA8) CTG CAG expansion produces
CUG expansion RNAs (CUG
exp) from the ATXN8OS gene and a nearly pure polyglutamine expansion protein encoded by
ATXN8 CAG
exp transcripts expressed in the opposite direction. Here, we present three lines of evidence that RNA gain-of-
function plays a significant role in SCA8: 1) CUG
exp transcripts accumulate as ribonuclear inclusions that co-localize with
MBNL1 in selected neurons in the brain; 2) loss of Mbnl1 enhances motor deficits in SCA8 mice; 3) SCA8 CUG
exp transcripts
trigger splicing changes and increased expression of the CUGBP1-MBNL1 regulated CNS target, GABA-A transporter 4 (GAT4/
Gabt4). In vivo optical imaging studies in SCA8 mice confirm that Gabt4 upregulation is associated with the predicted loss of
GABAergic inhibition within the granular cell layer. These data demonstrate that CUG
exp transcripts dysregulate MBNL/CELF
regulated pathways in the brain and provide mechanistic insight into the CNS effects of other CUG
exp disorders. Moreover,
our demonstration that relatively short CUG
exp transcripts cause RNA gain-of-function effects and the growing number of
antisense transcripts recently reported in mammalian genomes suggest unrecognized toxic RNAs contribute to the
pathophysiology of polyglutamine CAG CTG disorders.
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Introduction
Spinocerebellar ataxia type 8 (SCA8), is a slowly progressive
neurodegenerative disease caused by a CTGNCAG expansion that
primarily affects the cerebellum [1,2]. The disease is transmitted in
an autosomal dominant pattern with reduced penetrance and the
expansion mutation was originally shown to be expressed as a
CUG expansion (CUG
exp) transcript in the 39region of an
untranslated gene, ATXN8OS. BAC transgenic mice expressing
the SCA8 expansion (SCA8 BAC-EXP, [CTG]116) but not a
control repeat (SCA8 BAC-CRTL, [CTG]11) from the endoge-
nous human promoter develop progressive motor deficits and a
loss of cerebellar GABAergic inhibition [3]. Unexpectedly, SCA8
patients and BAC-EXP mice were found to have 1C2-positive
intranuclear inclusions in Purkinje cells and brainstem neurons
that result from the expression of a nearly pure polyglutamine
protein (ataxin 8) from a novel gene spanning the repeat in the
opposite CAG direction (ATXN8). The expression of CUG
exp
transcripts from ATXN8OS in addition to CAG
exp transcripts and
a polyglutamine protein from ATXN8 suggests that SCA8 involves
toxic gain-of-function effects at both the RNA (CUG
exp) and
protein (PolyQ) levels. An alternative hypothesis is that the SCA8
expansion affects the expression of an overlapping gene, KLHL1
and although Klhl1 knockout mice have a subtle phenotype, the
relevance of this model to the human disease is unclear [4].
Substantial evidence that CUG
exp RNAs are toxic comes from
studies of the neuromuscular disease myotonic dystrophy (DM)
where CUG
exp (DM1) and CCUG
exp (DM2) RNAs alter the
activities of two families of alternative splicing factors, the MBNL
and CELF proteins [5,6]. Multiple lines of evidence support the
model that these expansion transcripts cause disease specific
clinical features. First, transgenic mouse models of DM1 in which
CUG
exp transcripts are expressed in the 39 UTR of the DM1
(DMPK), or the unrelated human skeletal muscle actin (HSA), gene
cause skeletal muscle myotonia and myopathy similar to human
DM skeletal muscle pathology [7,8]. In addition, CUG
exp or
CCUG
exp transcripts accumulate as ribonuclear inclusions in
DM1 and DM2 patient skeletal muscle [9–11] and alter the
localization or regulation of RNA binding proteins CUGBP1
[12,13] and MBNL1 [14,15]. Additional studies show expression
of CUG
exp transcripts induce alternative splicing changes in
skeletal muscle genes associated with disease symptoms including
the chloride channel (CLCN1) and insulin receptor genes (IR) [16–
19]. Similar alternative splicing events in numerous genes have
now been shown to be misregulated in myotonic dystrophy, often
causing aberrant expression of fetal isoforms in adult tissue [5].
PLoS Genetics | www.plosgenetics.org 1 August 2009 | Volume 5 | Issue 8 | e1000600Evidence that MBNL1 loss-of-function plays a role in DM was
suggested by studies showing MBNL1 co-localizes with CUG or
CCUG ribonuclear inclusions [10] with additional strong support
coming from Mbnl1 isoform knockout mice (Mbnl1
DE3/DE3) that
recapitulate several aspects of the multisystemic disease pathology
and misregulated splicing events characteristic of DM [20].
Furthermore, MBNL1 has been shown to bind directly to intronic
elements of genes misregulated in DM cardiac and skeletal muscle
(cTNT and IR) and to promote alternative splicing patterns
normally found in adult tissue [21]. Taken together, these data
suggest that expression of CUG
exp or CCUG
exp transcripts
induces alternative splicing changes in DM skeletal and cardiac
muscle by sequestration and functional loss of MBNL1 protein.
In addition to skeletal and cardiac muscle disease, behavioral
and cognitive changes in DM suggest that CUG
exp and CCUG
exp
transcripts also cause CNS effects. DM1 CUG
exp transcripts form
ribonuclear inclusions that co-localize with MBNL1 in temporal
lobe neurons of DM1 patients [22]. Additionally, alternative
splicing changes in a number of CNS transcripts (NMDA R1, APP,
MAPT/Mapt, Mbnl1) are found in humans and mice [22,23].
Although the mechanism for these CNS splicing changes is
unknown, these data suggest that DM, and possibly the much
shorter SCA8 CUG expansion transcripts, cause RNA gain-of-
function effects in brain.
In support of the model that SCA8 CUG
exp transcripts affect
MBNL1 regulated pathways, expression of human SCA8 cDNA
transcripts (ATXN8OS) in Drosophila photoreceptor neurons
induce a late-onset, neurodegenerative phenotype genetically
enhanced by the loss of the fly MBNL1 orthologue muscleblind
[24]. This result is similar to fly models of DM1 [25,26] and
consistent with additional evidence for RNA gain-of-function
effects in DM.
In this study, we present the first evidence that SCA8 CUG
exp
transcripts cause ‘‘RNA gain-of-function’’ effects in the brain.
First, we demonstrate that SCA8 CUG
exp transcripts form
hallmark ribonuclear inclusions that co-localize with MBNL1 in
humans and mice and that genetic loss of Mbnl1 enhances motor
coordination deficits in SCA8 BAC-EXP mice. Additionally, we
show that expression of ATXN8OS CUG
exp transcripts dysregulate
MBNL1-CUGBP1 pathways in the CNS and trigger downstream
molecular changes in GABA-A transporter 4 (Gabt4) regulation
through an RNA gain-of-function mechanism.
Results
Co-Localization of CUG
exp Ribonuclear Inclusions with
MBNL1 in SCA8 Brain
To determine if SCA8 ATXN8OS transcripts form ribonuclear
inclusions similar to those found in DM, fluorescence in-situ
hybridization (FISH) was preformed on SCA8 human and SCA8
BAC-EXP mouse cerebella using a Cy5-labeled (CAG)10 oligonu-
cleotide probe. In human SCA8 autopsy tissue, CUG positive
inclusions were found in the cerebellar cortical layers (red dots) by
confocal microscopy. These CUG ribonuclear inclusions are
distinguishablefrom background lipofuscinauto-fluorescencewhich
appears as a yellowish-brown perinuclear staining (Figure 1A).
Although ribonuclear inclusions were seen in all three SCA8
autopsy brains examined, the foci varied in distribution, size, and
number between SCA8 cases and compared to ribonuclear
inclusions found in DM1 cerebellum. In cerebellar tissue from
SCA8 patients with 1000 and 400 CTG repeats, single CUG foci
were frequently found in the nuclei of molecular layer (ML)
interneurons and the Bergmann glia surrounding the Purkinje cells
in the granule cell (GC) layer, while multiple smaller foci were
typically found in Purkinje cells (PC). Although qRT-PCR shows
CUG
exp transcripts are expressed at comparable levels in all three
SCA8 autopsy cases, ribonuclear inclusions were not reproducibly
found inthe brainwith109 CTG repeats, and were only detected in
a single molecular layer interneuron (not shown). While these data
suggest that ribonuclear inclusions are less likely to form in patients
with shorter expansions, CUG RNA foci were readily detectable in
SCA8 BAC transgenic mice which express similarly sized SCA8
ATXN8OS (CUG)116 transcripts under the control of the endoge-
nous human promoter (Figure 1A, bottomrow). Similar totheRNA
foci found in SCA8 autopsy tissue with 400 and 1000 repeats, the
foci in these mice have a similar distribution in the cerebellar cortex
(Purkinje cells, Bergmann glia, and molecular layer interneurons).
Additionally, ribonuclear inclusions were found in the deep
cerebellar nuclei in our mice, an area of the brain we were not
able to examine in the human autopsy cases. No foci were seen in
mice expressing normal repeat (CTG)11 or non-transgenic litter-
mates and additionally, no CAG foci were detected using a CTG
oligonucleotide probe (not shown).
FISH combined with immunofluorescence (IF) was performed
to determine if the SCA8 ribonuclear inclusions co-localize with
MBNL1. In human cerebellar sections, MBNL1 co-localizes with
the CUG foci in molecular layer interneurons (Figure 1B). In
contrast, SCA8 and DM1 Purkinje cells have clearly detectable
nuclear CUG foci but these foci do not co-localize with MBNL1,
which is predominantly expressed in the cytoplasm (Figure 1B,
middle and bottom row arrows). Similar to the human results,
SCA8 mice expressing the expansion, but not the control repeat,
have CUG-positive ribonuclear inclusions that co-localize with
Mbnl1 in molecular layer interneurons and deep cerebellar nuclei
(Figure 1C) but not in Purkinje cells (not shown).
Reduced Mbnl1 Enhances Rotarod Deficits in SCA8-BAC-
EXP Mice
Because co-localization of MBNL1 with CUG
exp ribonuclear
inclusions is thought to lead to functional impairment of nuclear
Author Summary
We describe several lines of evidence that RNA gain-of-
function effects play a significant role in spinocerebellar
ataxia type 8 (SCA8) and has broader implications for
understanding the CNS effects of other trinucleotide
expansion disorders including myotonic dystrophy type
1, Huntington disease like-2, and spinocerebellar ataxia
type 7. The SCA8 mutation is bidirectionally transcribed
resulting in the expression of CUG
exp transcripts from
ATXN8OS and CAG
exp transcripts and polyglutamine
protein from the overlapping ATXN8 gene. These data
suggest that SCA8 pathogenesis involves toxic gain-of-
function effects at the RNA (CUG
exp) and/or protein (PolyQ)
levels. We present three lines of evidence that CUG
exp
transcripts play a significant role in SCA8: 1) CUG
exp
transcripts accumulate as ribonuclear inclusions that co-
localize with MBNL1 in selected neurons; 2) loss of Mbnl1
enhances motor deficits in SCA8 mice; 3) SCA8 CUG
exp
transcripts trigger alternative splicing changes and in-
creased expression of the CUGBP1-MBNL1 regulated CNS
target, GABA-A transporter 4 (GAT4/Gabt4) which is
associated with the predicted loss of GABAergic inhibition
within the granular cell layer in SCA8 mice. Additionally,
alternative splicing changes and GAT4 upregulation are
induced by CUG
exp but not CAG
exp transcripts. From a
therapeutic viewpoint, it is promising that this change is
reversed in cells overexpressing MBNL1.
SCA8 RNA Gain of Function
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exp–positive ribonuclear inclusions and co-localization with MBNL1 in SCA8 cerebellum. (A) CUG-positive nuclear foci
(RED) in SCA8 mouse and human cerebellum. CUG ribonuclear inclusions detected by FISH (RED) in SCA8 (human and mouse) and DM1 (human)
Purkinje cells (PCs), molecular layer (ML) interneurons (human and mouse), and deep cerebellar nuclei (DCN) (mouse) showing CUG positive nuclear
foci (RED) in human SCA8 and DM1 cerebellum (top) and in SCA8 BAC-EXP1 mice (bottom). (B) FISH and IF analysis of CUG foci and MBNL1 in human
cerebellar autopsy tissue. CUG foci co-localize with MBNL1 in molecular layer interneurons (ML) (SCA8) (top row; arrowheads) but not in Purkinje cells
(PC) (SCA8 or DM1) (middle and bottom rows, arrows). Co-localization is indicated by a yellowish color when the red CUG foci, green MBNL1 and blue
DAPI overlap in the nucleus. (C) CUG foci co-localize with Mbnl1 in ML interneurons and deep cerebellar nuclei (DCN) in SCA8 BAC-EXP mice
(arrowheads, top and bottom rows). Images are representative examples of staining with all 3 channels acquired at equal intensities in sequential
order on a confocal microscope, merged along the Z-axis, digitally zoomed, cropped, and adjusted for brightness and contrast for publication.
doi:10.1371/journal.pgen.1000600.g001
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of-function effects in SCA8 contribute to the motor deficits in
SCA8 BAC-EXP mice via Mbnl1 depletion. Mice from a low copy
SCA8 BAC-EXP5 line (SCA8 BAC-EXP5
+/2) were crossed to
heterozygous Mbnl1 isoform knockout mice (Mbnl1
+/DE3). Mice
from the SCA8 BAC-EXP5
+/2 line were selected for these studies
because these animals, which have normal rotarod performance at
26 weeks of age, do not develop a movement disorder phenotype
until .1 year of age [3]. Additionally, although homozygous
Mbnl1
DE3/DE3 knockout mice model the multisystemic features of
DM pathology heterozygous Mbnl1
+/DE3 mice are similar to wild
type and do not develop myotonia or other skeletal muscle
changes [20]. To test if genetic Mbnl1 loss enhances the SCA8
CNS phenotype we crossed heterozygous SCA8 BAC-EXP5
+/2
mice to heterozygous Mbnl1
+/DE3 knockout mice and tested the F1
offspring [(SCA8
+/2 (n=11); Mbnl1
+/DE3 (n=13); SCA8
+/2;
Mbnl1
+/DE3 (n=17) and non-transgenic littermates (n=9)] for
motor deficits at 26 weeks of age by rotarod analysis. The latency
to fall in seconds (sec) was recorded for 4 trials per day over 4
consecutive days. Mean differences between groups for each testing
day were determined by taking the average of the last 3 trials.
Consistent with previous results [3], no significant difference in
mean latency to fall was found between the SCA8 BAC-EXP5
+/2
mice (409.52622.51 sec) and non-transgenic littermates
(414.83622.18 Sec.; P=0.86). Although heterozygous Mbnl1
+/DE3
mice did have a significantly different mean latency to fall
(342.15618.75 sec.) comparedtonon-transgenic littermates [F(1,86)=
6.22; P=0.012], double mutant offspring (SCA8
+/2; Mbnl1
+/DE3)
performed significantly worse (273.69614.13 Sec) than either the singly
mutant Mbnl1
+/DE3 (P=0.003) or SCA8 BAC-EXP5
+/2 littermates
[F(1,102)=31.27; P,0.00001] (Figure 2). These data provide genetic
evidence that loss of Mbnl1 plays a role in SCA8 pathogenesis and
support the hypothesis that SCA8 CUG
exp transcripts affect Mbnl1
regulated pathways in the brain.
Identification of Candidate RNA Gain-of-Function Targets
by Cross-Linking and Immunoprecipitation (CLIP)
The discovery that CUG
exp RNA and MBNL1 protein co-
accumulate in ribonuclear foci in neurons suggests that, similar to
the dysregulation of MBNL/CELF pathways in DM muscle, the
accumulation of SCA8 CUG expansion transcripts might lead to
the dysregulation of developmentally regulated splicing patterns in
SCA8 brain. Further support for this hypothesis comes from
alternative splicing changes found in MBNL1 and NMDAR1 in
SCA8 autopsy brains (Figure 3A) which mimic previously reported
changes in DM1 [22,27]. To identify novel splicing targets that
might be affected by Mbnl1 loss or increased Cugbp1 activity we
used cross-linking and immunoprecipitation (CLIP) analysis [28]
on mouse postnatal day 8 (P8) hindbrains. CLIP was successful in
identifing RNA targets of Cugbp1 but not Mbnl1. Because CUG-
BP1 and MBNL1 have been shown to be antagonistic regulators of
alternative splicing of a number of different targets from work
done in the myotonic dystrophy field, we reasoned that CUG-BP1
CLIP tags would be also be good candidate targets for MBNL1
regulation. At P8, hindbrain can be readily dissociated into a cell
suspension which was then exposed to UV-light to fix RNA-
protein complexes formed in vivo. This procedure avoids artifacts
associated with immunopurification of unfixed proteins which may
redistribute during in vitro manipulation. Cross-linked RNA-
protein complexes were treated with RNase T1, to generate
relatively short (60–200 nt) CLIP RNA tags, and immunopurified
with a monoclonal antibody against Cugbp1. Complexes were
then subjected to electrophoresis/electroblotting and filter-
retained RNA tags were identified following cDNA conversion,
amplification and DNA sequencing. A total of 315 Cugbp1-
associated RNA tags were identified representing 206 genes with
53 multi-hit tags (Figure 3B and Table S1). While the majority of
these tags were intronic (64%), in agreement with a previous study
on the splicing regulator Nova1 [28], a significant number (25%)
were positioned within 39 untranslated regions (UTRs). Sequence
analysis revealed that Cugbp1 CLIP tags were enriched in UG
repeats consistent with previous three-hybrid and SELEX studies
which have indicated that the highest affinity sites for CUGBP1,
CUGBP2 and CELF4 are (UG)n, and (UGUU)n repeats [29,30].
A recent study identified a GU-rich 11-mer element (GRE)
UG(U)3G(U)3GU, which is enriched in the 39-UTRs of short-lived
transcripts, as a CUGBP1 binding motif [31]. Interestingly, only
one Cugbp1 39 UTR CLIP tag (Slc22a5), and two intronic tags
(Lrrc9, Samd12), contained this GRE motif (see Table S1).
Figure 2. Loss of MBNL1 enhances rotarod deficits in SCA8
BAC-EXP5 mice. (A) Line plot of average latency to fall in seconds
over four consecutive trial days. Individual trial day data points are the
average of the last 3 trials and show a decreased latency for SCA8
+/2;
Mbnl1
+/DE3 mice that is significantly different from WT at day four. (B)
Bar graph shows the mean latency to fall (Sec) for non-transgenic, singly
transgenic SCA8 BAC-EXP5 (SCA8
+/2). heterozygous Mbnl1 knock-out
(Mbnl1
+/DE3)anddoublytransgenicSCA8BAC-EXP5;Mbnl1
+/DE3(SCA8
+/2;
Mbnl1
+/DE3; n=17) littermates. As previously reported for this low-
copy line (SCA8 BAC-EXP5), no significant difference between non-
transgenic littermates and singly transgenic SCA8
+/2 animals was
found. Although singly transgenic Mbnl1
+/DE3 mice show a significant
decrease in latency compared to non-transgenic (p=0.01), doubly
mutant SCA8
+/2; Mbnl1
+/DE3 perform significantly worse than both WT
and singly mutant Mbnl1
+/DE3 animals (p=0.003). *and {=significant
differences between groups.
doi:10.1371/journal.pgen.1000600.g002
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gamma-aminobutyric acid (GABA-A) transporter 4 gene, Gabt4, because
previousinvivofunctional imaging studiesshowed a lossofcerebellar
GABAergic inhibition in our SCA8-BAC-EXP mice [3]. Further
analysis of the Gabt4 CLIP tag showed that the putative Cugbp1
binding site maps to exon 7 (and overlaps the exon 7 59 splice site)
which is highly conserved in human and mouse. The gene name in
mouse is Gabt4/Slc6a11 and in human GAT3 but for clarity referred
to here as Gabt4 and GABT4, respectively.
Upregulation of GABA-A Transporter 4 (Gabt4) and
Functional Granular Cell Layer Changes in SCA8 Mice
Since Gabt4 was identified as a putative target of CUGBP1 by
CLIP analysis and because increased Gabt4 expression could
explain the increased cortical loss of GABAergic inhibition
previously reported in our mice by reducing GABA at the
synapse, we hypothesized that SCA8 CUG
exp RNA dysregulates
Cugbp1 and Mbnl1 pathways resulting in an increase in Gabt4
expression. Consistent with this idea, we found significant
increases in cerebellar Gabt4 protein and RNA levels by protein
blot (5.3661.11 fold; p=0.003) and qRT-PCR (2.7260.68 fold
p=0.0015) in SCA8 BAC-EXP1 mice compared to non-
transgenic littermates (Figure 4A and 4B) while no increase was
seen in SCA8 BAC-CTRL animals (Figure 4B). Further
supporting the hypothesis that Gabt4 increases in SCA8 are
caused by sequestration of Mbnl1 by SCA8 CUG
exp transcripts,
Gabt4 protein and transcript levels are also higher in Mbnl1
DE3/DE3
knockout mice compared to strain matched (129/B6) non-
transgenic littermate controls with a 2.4960.083 (P,0.001) and
2.2960.32 (P=0.013) mean fold increase by protein blot and
qRT-PCR, respectively (Figure 4A and 4B). The increases in
Gabt4 protein were reproducible in both high copy number SCA8
BAC-EXP lines studied (BAC-EXP1 and BAC-EXP2) but more
variable in mice from the lower copy number BAC-EXP5 line
(data not shown) consistent with the decreased penetrance
reported previously in this line. In addition, no similar changes
were seen in Gabt1 levels, another member of GABA-A
transporter family expressed in cerebellum indicating that changes
seen in Gabt4 are not caused by a general upregulation of GABA-A
transporters (Figure 4C).
Immunofluorescence studies show expression of Gabt4 protein is
primarily localized to the granular cell layer of the cerebellar cortex
and the deep-cerebellar nuclei (DCN) and that no overt change in
this distribution is seen (Figure 4D) between wildtype and SCA8
BAC-EXP1 mice. To further characterize the loss of inhibition
phenotype and the possible role of Gabt4 we examined the SCA8
BAC mice for functional changes in the granular layer of the
cerebellum, the site of highest Gabt4 expression using flavoprotein
optical imaging in response to whisker pad stimulation in SCA8
mice[32,33]. Activationof cerebellar granule cells by mossy fibers is
in part controlled by Golgi cell mediated feedback that produces
GABAergicinhibitionofgranulecells[34]. Because the clearanceof
synaptically released GABA in the granular layer is predominately
mediated by Gabt4, up-regulation of Gabt4 would be expected to
reduce this Golgi mediated inhibition and enhance the responses to
mossy fiber input. The imaging data collected confirm this
prediction. Whisker pad stimulation evokes a patch-like response
(Figure 4E) consistent with previous electrophysiological and
imaging studies [32,35]. There is a significant increase in both the
intensity and area of the response in Crus II in the SCA8 BAC-Exp
(n=5) compared with FVB mice (n=7) (Figure 4, p,0.05).
Therefore,up-regulation ofGabt4inthegranular layerisassociated
with the expected increase in the response to mossy fiber inputs
activated by peripheral stimulation.
In summary, these data demonstrate that Gabt4, a gene
identified by CLIP analysis as a Cugbp1 target, is upregulated at
Figure 3. Alternative splicing changes in SCA8 and CUGBP1 RNA targets. (A) RT-PCR of human autopsy tissue showing alternative splicing
changes previously reported for DM1, NMDAR1 (exon 5) and MBNL1 (exon 7) also occur in SCA8. B) Diagram summarizing relative position of CUG-
BP1 CLIP tags in genes. Boxes=exons (open=UTR; black-ORF); thick grey line=intergenic regions. Also indicated are tags that overlap intron/exon,
orf/39 UTR and 39 UTR/intergenic junctions with the number of unique tags for each location in parentheses.
doi:10.1371/journal.pgen.1000600.g003
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DE3/DE3 mice. (A) Example immunoblot showing increase in Gabt4 protein in
SCA8 BAC-EXP1 and Mbnl1
DE3/DE3 mice relative to strain specific WT controls. Bar graph shows average Gabt4 protein quantified by densitometry
methods, and analyzed for mean between group differences compared to strain specific wild type animals. Asterisks=significant differences for SCA8
(p,0.002) and Mbnl1
DE3/DE3 (p,0.001) mice compared to non-transgenic controls. (B) qRT-PCR showing increased Gabt4 vs. Hprt in SCA8 BAC-EXP
and Mbnl1
DE3/DE3 compared to BAC-CTRL and non-transgenic littermates. Asterisks=statistical significance, p=0.0015 for SCA8 and p,0.01 for
Mbnl1
DE3/DE3 mice compared to non-transgenic controls. (C) Example protein blot showing no change in another prominent cerebellar GABA
transporter receptor, Gabt1, in SCA8 BAC-EXP1 mice. (D) Fluorescent IHC staining showing a similar distribution with a qualitative increase in Gabt4I F
in cerebellar granular cell layer in SCA8 BAC-EXP1 compared to wildtype mice. (E) Optical responses in Crus II to stimulation of the ipsilateral C3
whisker pad in FVB and SCA8 mice showing increased cerebellar cortical response to whisker pad stimulation in SCA8 mice. Shown are the
thresholded (mean61 SD of the control region) and pseudocolored responses superimposed on an image of the background fluorescence. Scale
bar=1 mm. Both the intensity and area of the responses were greater in the SCA8 mice compared with FVB control mice. *denotes p,0.05.
doi:10.1371/journal.pgen.1000600.g004
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Mbnl1
DE3/DE3 knockout animals but not in the SCA8 BAC-CTRL
mice expressing a normal length CUG11 repeat. Additionally,
Gabt4 upregulation in these mice is associated with the predicted
loss of GABAergic inhibition within the granular cell layer.
GABT4 Upregulation and Alternative Splicing in SCA8
Human Autopsy Tissue
To determine if GABT4 upregulation also occurs in humans, we
examined steady-state RNA and protein levels in human SCA8
autopsy brains. While expression of the SCA8 CUG
exp and
CAG
exp transcripts and GABT4 overlap in both the cerebellum
and the frontal lobe, only frontal lobe tissue was suitable for
analysis because of significant cell loss in the cerebellum caused by
neurodegeneration in SCA8 patients. Total RNA extracted from
adult SCA8, DM1 and control and from 26-week fetal frontal
cortex was examined by qRT-PCR using primers to exons 1 and
2. SCA8 autopsy brains (n=3) showed increased GABT4
transcripts levels compared to adult control (p,0.01) (Figure 5A)
and similar levels to those found in fetal tissue. A similar trend of
increased GABT4 protein was also seen in SCA8 and fetal brain
compared to adult control or DM1 tissue (Figure 5B).
Because exon 7 of Gabt4 was identified as a potential Cugbp1
binding site, we investigated if increases in GABT4 expression
could be related to misregulation of exon 7 alternative splicing.
Consistent with this hypothesis, all three human SCA8 autopsy
brains showed a shift in alternative splicing favoring inclusion of
GABT4 exon 7 containing transcripts compared to adult control
(Figure 5C). Preferential exon 7 inclusion was also seen in control
human fetal autopsy tissue but not in adult DM1 tissue and is
correlated with the increases in GABT4 RNA and protein seen in
SCA8 adult and control fetal brain (Figure 5). Interestingly, no
exon 7 splicing shifts or increases in GABT4 expression were found
in DM1 autopsy tissue, possibly reflecting differences in spatial or
temporal expression of the SCA8 and DM1 CUG
exp transcripts.
Similar to the dysregulation of other genes inDM, SCA8 CUG
exp
transcripts trigger a shift in the ratios of alternatively spliced human
GABT4 (+/2 exon 7) transcripts that resemble those found during
fetal development. Sequence analysis shows that transcripts skipping
exon 7 would lead to the introduction of a premature termination
codon (PTC) which would be predicted to target (2)e x o n7
transcripts for nonsense mediated decay (NMD). These data suggest
a model in which developmental alternative splicing changes in
human normally lead to lower levels of GABT4 in adult tissue and
higher levels in SCA8 and during fetal development.
Similar to humans, Gabt4 is also up-regulated in the SCA8 BAC-
Expand Mbnl1
DE3/DE3mice.Althoughalternative splicingofexon 7
has not yet been detected in the mouse by RT-PCR, exclusion of
mouse exon 7 would also create a PTC (in exon 10) that would be
predicted to lead to NMD. Further studies are needed to determine
ifNMDinthemouseleadstomoreefficient degradationof(2)exon
7 transcripts which prevent their detection or if Gabt4 upregulation
in the mouse occurs via another mechanism.
SCA8 CUG
exp Not CAG
exp Transcripts Misregulate GABT4
Pre–mRNA Alternative Splicing and Expression in SK-N-
SH Cells
To test directly if increases in GABT4 are induced by SCA8
CUG
exp or CAG
exp transcripts, we examined their effects in
human neuroblastoma SK-N-SH cells. Transient transfections
were performed using minigenes (Figure 6A) designed to express
SCA8 CUG (SCA8-CTG
exp) or CAG expansion transcripts
(SCA8-REV CAG
exp). Cells expressing SCA8 CUG
exp transcripts
show significant increases in GABT4 RNA levels by qRT-PCR
relative to untransfected cells (p=0.007) or to cells transfected with
vector alone (p=0.006) while expression of the SCA8 CAG
exp
construct compared to vector alone had no effect (p=0.72)
(Figure 6B). Additionally, transient transfections of minigenes
without ATXN8 and ATXN8OS flanking sequence show poly-
CUG105 but not poly-CAG105 transcripts up-regulate GABT4
RNA (p=0.001) (Figure 6C). Further analysis using primers
flanking exon 7, show cells expressing higher levels GABT4
transcripts also preferentially express higher ratios of exon 7
included transcripts. (Figure 6B and 6C).
MBNL1 Overexpression Reverses SCA8 CUG
exp–Induced
Misregulation of GABT4 in SK-N-SH Cells
To test if GABT4 expression is antagonistically regulated by
CUGBP1 and MBNL1, we transfected SK-N-SH cells using GFP-
Figure 5. Upregulation and alternative splicing of GABT4 in
human SCA8 brain. (A) qRT-PCR shows increased GABT4 RNA in
frontal lobe autopsy tissue from adult SCA8 (n=3) and control fetal
(n=1) tissue. *=significant difference (p,0.01). (B) Protein blot
showing up-regulation of GABT4 in SCA8 and fetal frontal lobe vs.
DM1 and Control with GAPDH as loading control. (C) RT-PCR of GABT4
shows a shift favoring exon 7 inclusion transcripts in SCA8 and control
fetal frontal lobe tissue vs. adult control and DM1.
doi:10.1371/journal.pgen.1000600.g005
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inducing alternative splicing changes in cell culture [21,36]. As
above, alternatively-spliced exon 7 transcripts were assayed by
RT-PCR with primers located in GABT4 exons 6 and 8 and
primers spanning exons 1 and 2 were used to assess endogenous
levels of GABT4 by qRT-PCR. Cells overexpressing CUGBP1
(p,0.0001) or SCA8 exon A CTG
exp minigenes show increases in
GABT4 RNA (p=0.003) and a concomitant increases in protein
and a splicing shift favoring exon 7 inclusion compared to vector
alone (Figure 7A–7C). While no change in GABT4 RNA or
protein was seen in cells overexpressing MBNL1/41 alone,
overexpression of MBNL1/41 and SCA8 CUG
exp transcripts
reverses the increase in GABT4 RNA (p,0.0001) and protein
(Figure 7A and 7C) triggered by SCA8 CUG
exp transcripts alone
and restores exon 7 alternative splicing ratios to the normal adult
pattern (Figure 7B). Sequence analysis of the GABT4 RT-PCR
products confirm the upper and lower bands include and exclude
exon 7 respectively and that the (-) exon 7 transcripts have a
premature stop codon in exon 8. Taken together, these results are
consistent with a model in which SCA8 CUG
exp transcripts alter
the regulation of GABT4 by sequestration of MBNL1 and/or an
increase in the expression or activity of CUGBP1.
Discussion
The SCA8 CTG CAG mutation is bidirectionally expressed
and produces both CUG and CAG-expansion transcripts and a
nearly pure polyglutamine expansion protein [3]. We investigated
RNA gain-of-function effects in SCA8 and present three lines of
evidence that CUG
exp transcripts play a role in SCA8. First, we
demonstrate CUG
exp transcripts accumulate as ribonuclear
inclusions in selected cells and that these RNA foci co-localize
with Mbnl1 in a subset of neurons in SCA8 patients and mice.
Second, we show genetic loss of Mbnl1 enhances motor
coordination deficits in low-copy SCA8 BAC
exp mice. Third, we
demonstrate SCA8 CUG
exp transcripts trigger increased expres-
sion of a CUGBP1-MBNL1 regulated CNS target, GABT4,i n
both mice and humans as well as in a human cell culture model
and demonstrate the predicted loss of GABAergic inhibition
within the granular cell layer occurs in these animals.
Figure 6. Endogenous GABT4 up-regulation in SK-N-SH cells induced by CUG
exp but not CAG
exp transcripts. (A) Schematic of constructs
used to express SCA8 CUG
exp or CAG
exp and pure CUG
exp and CAG
exp transcripts. (B) qRT-PCR shows increased GABT4 RNA levels in SK-N-SH cells
expressing Exon A CUG
exp or pure polyCUG
exp transcripts. *=statistical significance, p,0.0001. (C) Alternative splicing shifts favoring exon 7 inclusion
in cells expressing SCA8 Exon A CUG
exp or pure polyCUG
exp that does not occur in response to SCA8 Exon A CAG or pure polyCAG
exp transcripts
compared to vector alone.
doi:10.1371/journal.pgen.1000600.g006
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myotonic dystrophy, mechanistic studies have focused on skeletal
and cardiac muscle and little is known about the effects of CUG
exp
transcripts in brain. In addition, the antagonistic relationship
between CUGBP1 and MBNL1, previously documented in heart
and skeletal muscle, has not been demonstrated in the CNS. In
this study we used CLIP analysis to identify putative Cugbp1 CNS
targets. To explore the molecular basis of the loss of GABAergic
inhibition we investigated changes in expression levels and
alternative splicing of the Cugbp1 CLIP target, Gabt4, in our
mice. We show that overexpression of CUGBP1 in human SK-N-
SH cells, or depletion of MBNL1, result in an upregulation of
GABT4 that mimics the in vivo changes in steady state levels caused
by CUG
exp transcripts. These data provide the first evidence that
CUG
exp RNA gain-of-function effects in the brain involve the
dysregulation of CUGBP1-MBNL1 pathways. These data also
suggest that MBNL1 overexpression, which has been demonstrat-
ed to be therapeutic in skeletal muscle, might also be an effective
treatment to reverse pathological changes associated with
expression of CUG
exp transcripts in the CNS. Additionally, the
long list of other putative Cugbp1 targets identified in mouse brain
provides an important future resource for the identification of
additional CNS genes dysregulated in SCA8 and DM.
Previous studies in myotonic dystrophy suggest that the
expression of CUG
exp transcripts, together with MBNL1 and
CELF proteins and their downstream target genes need to be
coordinated temporally and spatially for disease pathogenesis.
Therefore, defining the temporal and cell specific ATXN8OS
expression pattern will be crucial for understanding disease
pathogenesis and interpreting future results. We identified for
the first time in SCA8, CUG-RNA foci in Purkinje cells, molecular
layer interneurons and the deep cerebellar nuclei. In addition, we
show MBNL1/Mbnl1 colocalizes with SCA8 CUG foci in
molecular layer interneurons and the DCN. Interestingly,
although Purkinje cells had nuclear CUG foci in both DM1 and
SCA8, co-localization with nuclear MBNL1 was not observed in
these cells. Further studies will need to be done to determine if
MBNL1 is expressed in the nucleus of these cells or if changes in
MBNL1 splice forms affect its ability to bind to the CUG
expansion transcripts. Taken together, these results suggest that
temporal and spatial expression patterns of expansion transcripts
and the overlap in expression of specific RNA binding proteins
and their downstream target genes are likely to underlie the
susceptibility of specific cells to RNA gain-of-function effects and
the clinical difference between DM and SCA8.
To investigate the broader significance of MBNL1 in SCA8, we
tested the effects of Mbnl1 depletion on a behavioral phenotype in
our SCA8 mice by crossing heterozygous Mbnl1
+/DE3 animals with
a low-copy SCA8-BAC-EXP5 line. The phenotypic enhancement
of the rotarod deficits found in the doubly transgenic animals with
Figure 7. Antagonistic Regulation of GABT4 by CUGBP1 and MBNL1 in SK-N-SH cells. (A,B) qRT-PCR showing increased GABT4 transcript
levels and alternative splicing changes favoring exon 7 inclusion in cells overexpressing CUG
exp transcripts or CUG-BP1 but not in cells overexpressing
MBNL1 1/41 or CUG
exp and MBNL1 1/41. (C) Protein blot showing GABT4 is increased in cells overexpressing CUG
exp transcripts or CUG-BP1, but not
in cells overexpressing MBNL1/41 alone or MBNL1/41 and CUG
exp transcripts.
doi:10.1371/journal.pgen.1000600.g007
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exp transcripts in
SCA8 and the subsequent downstream effects on Mbnl1 are
sufficiently significant to contribute to the movement disorder
phenotype found in SCA8.
GABT4 upregulation in human SCA8 autopsy tissue and cell
culture studies supports a model in which GABT4 levels are
regulated by alternative splicing changes and the NMD pathway.
Similar to the dysregulation of other genes in DM1 (CLCN-1, IR)
[5], the expression of CUG
exp but not CAG
exp transcripts [37]
triggers a shift in the ratios of alternatively spliced GABT4
transcripts that resembles those found during fetal development.
Further studies are needed to determine if GABT4 alternative
splicing changes occur throughout the brain and to directly show if
alternative splicing of exon 7 and NMD regulate GABT4/Gabt4
expression levels in both humans and mice. Additional studies are
also required to directly test the hypothesis that GABT4
upregulation causes the decrease in GABAergic inhibition seen
in our SCA8 BAC-EXP mice.
While these data provide the first evidence for RNA gain-of-
function effects in SCA8, it is also possible that the polyQ
expansion protein contributes to the disease. In contrast to other
disorders in which polyQ expansions are expressed as part of a
mature protein, the SCA8 CAG
exp is expressed as a nearly pure
polyQ tract. While previous studies have shown that pure polyQ
repeats are toxic in Drosophila and mice, the relative contribution
of RNA and protein gain-of-function effects in SCA8 still needs to
be assessed.
In this study we provide several lines of evidence that RNA
gain-of-function effects play a significant role in SCA8 and show
that SCA8 CUG
exp transcripts affect alternative splicing patterns
controlled by MBNL1 and CUGBP1 in the mammalian brain.
While SCA8 is the first reported disease in which a single
expansion mutation expresses both a polyglutamine protein and
CUG
exp transcripts, bidirectional expression has also been recently
described in other triplet expansion disorders. For example, sense
(CUG
exp) and antisense (CAG
exp) transcripts have been reported
at the DM1 locus [38]. Similarly, Huntington disease Like 2
(HDL2), another disease in which CUG
exp transcripts form
ribonuclear inclusions [39], also has 1C2-positive inclusions (1C2
is an antibody that recognizes polyglutamine expansions),
suggesting bidirectional expression may also occur in that disease
[40,41]. Additionally, bidirectional expression across the FMR1
CCG CGG repeat in Fragile X tremor ataxia patients has also
been reported [42]. Our data showing that relatively short (,110
repeats) CUG
exp transcripts can cause dysregulation of MBNL1/
CUGBP1 regulated pathways and the growing number of
antisense transcripts recently reported in mammalian genomes
[43], highlight the need to look for CUG transcripts expressed at
other loci traditionally associated with polyglutamine expansion
disorders.
Materials and Methods
FISH and Immunofluorescence
Fluorescent in-situ hybridization (FISH) and immunofluores-
cence (IF) was performed on frozen parasagittal cerebellar sections
(6 mm) as described [10]. Sections were fixed in 4% paraformal-
dehyde for 30, permeabilized in 2% acetone for 59, incubated in
30% formamide/2XSSC pre-hybridization for 1 hr at RT and
hybridized with a Cy5-(CAG)10 for 2 hr at 42
uC and post-
hybridized at 45
uC for 309. Sections were coverslipped and stained
with DAPI to identify CUG RNA foci or incubated overnight at
4
uC with Mbnl1 antibody (polyclonal A2764 gift of C.A.
Thornton) at 1:1000 and visualized by Alexa 488 secondary
antibody (1:2000) at RT for 309. A2764 is a polyclonal antibody,
directed against a C-terminal peptide of Mbnl1, specificity was
demonstrated by lack of reactivity on immunoblots from
Mbnl1
DE3/DE3 mice and the antibody recognizes all known
alternative splice isoforms of Mbnl1 [27]. Co-localization of
Cy5-(CAG)10 RNA foci with MBNL1 was done by confocal
microscopy (Olympus, Fluoview 1000) in 3 fluorescent channels
with $5 layers (0.5 mm) compressed along the Z-axis and then
merged. Gabt4 immunofluorescence staining was done using
10 mm frozen sections fixed using 4% paraformaldehyde for 309,
permeabilized with 2% acetone for 59, briefly washed with PBS
and then blocked in 5% goat serum, 0.3% Triton X-100 in PBS
for 2 hr at 4uC. Sections were incubated with anti-Gabt4
polyclonal antibody (human GAT3, Sigma, St. Louis, MO)
diluted 1:1000 in the same blocking solution for 24 hr at 4uC,
washed in PBS four times for 209 and incubated with secondary
antibody (Alexa 488 goat anti mouse IgG, Molecular Probes,
Eugene, OR) using a 1:2000 dilution for 2 hr at RT. Sections were
washed 5 times for 59 each in PBS and DAPI counterstained and
coverslipped using Vectastain with DAPI (Vectashield, Ca)
Rotarod Analysis
Rotarod training was performed at 26 weeks of age using an
accelerating rotarod (Ugo Basille, Comerio, Italy) as described [3].
All mice tested were F1 littermate progeny of single copy integrant
SCA8 BAC-EXP5
+/2 and Mbnl1
+/DE3 mice. Four trials were run
per day for four days: averages of the four trials on day four are
presented. rmANOVA followed by post-hoc analysis (Tukey’s
HSD) was performed to assess differences in rotarod performance
between groups (SCA8 BAC-EXP5
+/2; Mbnl1
+/DE3; SCA8 BAC-
EXP5
+/2/Mbnl1
+/DE3 and non-transgenic littermates).
Northern Analysis
For RNA analysis, 15 mg of total RNA isolated from non-
transgenic FVB or Bl6/129 wild type, SCA8 BAC-EXP1, SCA8
BAC-CTRL and Mbnl1
DE3/DE3 cerebellum was separated on a
Northern Max-Gly glyoxal gel (Ambion), transferred to a
nitrocellulose membrane, cross-linked by ultraviolet radiation
and hybridized at 65
uC in Rapid-Hyb buffer (Amersham) using
a[
32P]dUTP in vitro transcribed RNA probe to nucleotides 576–
996 (NM_172890.3) of the mouse Gabt4 gene. Expression analysis
was performed relative GAPDH by densitometry and analyzed by
one-way ANOVA with Tukey’s HSD post-hoc comparisons when
necessary.
Quantitative RT–PCR
Two step qRT-PCR was performed on an ABI Prism 7500 Real
Time PCR System (Applied Biosystems, Foster City, CA). Total
RNA was isolated from mouse cerebellum, human frontal lobe
autopsy tissue or transiently transfected SK-N-SH cells. cDNA was
generated from 5 mg of total RNA using 1
st Strand Synthesis
Supermix primed with random hexamers (Invitrogen). Relative
qRT-PCR was performed on 1 ml of cDNA with qRT-PCR
SYBER Green Master Mix UDG with ROX (Invitrogen) using
mouse specific primers (RSD1013 59- CCT CTG AAG GCA
TCA AGT TCT ATC TGT ACC-39) (RSD1014 59-GTT GTT
GTA ACT CCC CAG AGC GGT TAG-39) or human specific
primers for autopsy and SK-N-SH cells (RSD1009 59- AAC AAG
GTG GAG TTC GTG CT-39) (RSD1010 59- ACT TGT GAA
CTG CCC CAG AG-39). Two stage PCR was performed for 40
cycles (95
uC–1 5 0,6 0
uC– 19) in an optical 96 well plate with each
sample cDNA/primer pair done in triplicate. Relative quantifica-
tion compared to strain specific control was estimated using the
threshold cycle (Ct) of GABT4/Gabt4 normalized to the Ct of the
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respectively. Dissociation curve analysis and ethidium bromide gel
analysis was used to assess PCR product purity at the end of each
qRT-PCR run. Statistical analysis was done using rmANOVA on
the mean normalized Ct value of the 3 trials per sample and
compared by Tukey’s HSD post-hoc analysis for differences
between groups when necessary.
Immunoblotting
Animals were sacrificed and half of the cerebellum was rinsed
with PBS and lysed in 450 ml of RIPA buffer (150 mM NaC1, 1%
sodium deoxycholate, 1% Triton X-100, 50 mM Tris-HC1
pH 7.5, 100 ug/ml PMSF) for 459 on ice. Cell lysates were
centrifuged at 16,0006g for 159 at 4 uC and the supernatant was
collected. 20 mg of protein were separated on a 10% NuPAGE
Bis-Tris gel (Invitrogen), transferred to nitrocellulose membrane
(Amersham), blocked in 5% dry milk in PBS containing 0.05%
Tween 20 and probed with an anti-GAT4 antibody (human
GAT3; Sigma; 1:1000) or anti-GAT1 antibody (ABcam; 1:1,000)
in blocking solution and then incubated with anti-rabbit or anti-
mouse HRP conjugated secondary antibody (Amersham). Mean
fold increase in protein levels were determined by densitometry
normalized to GAPDH and compared to non-transgenic litter-
mates for each blot. Statistical significance was determined by one-
way ANOVA with between group comparisons evaluated by
Tukey’s HSD when necessary.
cDNA Constructs
ExonA of containing the SCA8 expansion was amplified by PCR
from the BAC transgene constr u c t ,B A C - e x p ,u s i n gt h e5 9 primer
(59CGAACCAAGCTTATCCCAATTCCTTGGCTAGACCC-39)
containing an added HindIII restriction site and the 39 primer
(59ACCTGCTCTAGATAAATTCTTAAGTAAGAGATAAGC-39)
containing an added XbaI restriction site. This HindIII/XbaI fragment
was cloned into the pcDNA3.1/myc-His A vector (Invitrogen, CA).
The SCA8 ExonA cDNA was placed under the control of the CMV
promoter of plasmid pcDNA3.1/myc-His. To construct ExonA-Rev,
the HindIII/XbaI fragment of SCA8 ExonA was subcloned in the
reverse orientation into pcDNA3.1/myc-His vector. The pCTG
exp
and pCAG
exp clones (108 repeats) were generated by PCR
amplification of SCA8 Exon A with added EcoRI restriction sites.
This EcoRI/EcoRI fragment was cloned into the pcDNA3.1/myc-
His A vector. The integrity of all constructs was confirmed by
sequencing. Both pEGFP-N1-CUGBP1 and pEGFP-C1-MBNL1/
41 have been described [27,44,45].
Cell Culture and Transfections
SK-N-SH cells were cultured in DMEM medium with 10%
fetal bovine serum at 37uC with 5% CO2. Transient transfections
were performed using 1 mg of SCA8 repeat expressing plasmids,
pEGFP-N1-CUGBP1, or pEGFP-C1-MBNL1/41 minigenes and
Lipofectamine 2000 Reagent (Invitrogen, Carlsbad, CA). Cells
were collected 48 hrs post-transfection for expression analysis.
Alternative Splicing
Analysis of NMDAR1 exon 5 and MBNL1 exon 7 alternative
splicing were conducted using total RNA collected from SCA8,
DM1 and control human brain autopsy tissue using Trizol
(Invitrogen, CA) reagent according to the manufactures procedures.
Human NMDAR1 exon 5 splicing was determined by amplification
of exon 4-5-6 using PCR primers hsGRIN1 ex4 For 59-
GCGTGTGGTTTGAGATGATG -39; hsGRIN1 ex6 Rev59-GG
TCAAACTGCAGCACCTTC -39. Similarly, exon 7 alternative
splicing of human MBNL1 was determined by amplification of exon
6-7-8 using PCR primers hsMBNL1 ex6 For 59-GCTGCCCAA-
TACCAGGTCAAC -39; hsMBNL1 ex8 Rev 59-TGGTGGGA-
GAAATGCTGTATGC -39. Determination of GABT4 exon 7
alternative splicing was done by reverse transcribing 2 mg total RNA
from frontal lobe or SKN-S-H cells as described above. 10% of this
reaction was subjected to PCR using primers (RSD1004 59-
GTTGTATACGTGACTGCGACATT-39; RSD1011 59-GTTC
AGGCAACAGAGCATGA-39) to amplify nucleotides 791 – 1057
of human GAT3 (NM_014229.1) for 25 cycles at 94
uC-450,5 4
uC-
300,7 2
uC-19 followed by 72
uCf o r6 9. PCR products were run out on
a 1.5% agarose gel with ethidium bromide and bands containing
exons 6-7-8 (267 bp) or 6–8 (163 bp) were cut and verified by
sequencing.
Identification of Cugbp1-Associated Transcripts
The crosslinking and immunoprecipitation protocol (CLIP) was
performed as described [28,46] with minor modifications.
Hindbrains were dissected from mouse postnatal day 8 (P8)
C57BL/6J pups followed by dissociation in 1X Hank’s balanced
salt solution containing 10 mM HEPES, pH 7.3 and UV-
irradiated to crosslink RNA-protein complexes. Cells were lysed
and RNA was partially digested with RNase T1 to produce 30–
200 nt fragments. Lysates were cleared by ultracentrifugation and
Cugbp1-bound fragments were immunoprecipitated using mAb
3B1 and Protein G Dynabeads (Invitrogen, Carlsbad, CA).
Following 39-end addition of RNA linkers, 59 ends were labeled
with g
32P-ATP, protein-RNA complexes were eluted, separated by
electrophoresis and protein-RNA complexes transferred to
nitrocellulose. Bands corresponding to 60–70 kDa (10–20 kDa
larger than the 50 kDa Cugbp1 protein) were excised from the
nitrocellulose and the RNAs released by proteinase K digestion.
RNA fragments were size fractionated by denaturing PAGE
followed by 59-end RNA linker ligation, RT-PCR and DNA
sequencing.
Animal Preparation and Flavoprotein Optical Imaging
All animal experimentation was approved by and conducted in
conformity with the Institutional Animal Care and Use Commit-
tee of the University of Minnesota. Experimental details on the
animal preparation, optical imaging and stimulation techniques
are only briefly described as these have been provided in previous
publications [32,33]. Mice (3–8 months old) were anesthetized
with urethane (2.0 mg/g body weight), mechanically ventilated,
and body temperature feedback-regulated. The electrocardiogram
was monitored to assess the depth of anesthesia. Crus I and II of
the cerebellar cortex were exposed and the dura removed. An
acrylic chamber was constructed around the exposed folia and
superfused with normal Ringer’s solution.
The animal was placed in the stereotaxic frame on an X-Y stage
mounted on a modified Nikon epifluorescence microscope fitted
with a 46objective and a 100 W mercury-xenon lamp. Images of
Crus I and II were acquired with a Quantix cooled charge coupled
device camera with 12 bit digitization (Roper Scientific). The
images were binned (262) to 2566256 pixels with a resolution of
,10 mm610 mm per pixel. Flavoprotein autofluorescence was
monitored using a band pass excitation filter (455635 nm), an
extended reflectance dichroic mirror (500 nm), and a.515 nm
long pass emission filter [33].
To evoke peripheral responses, the ipsilateral 3C vibrissal pad
was stimulated with a bipolar electrode (tips ,1 mm apart) using
20 V, 300 ms pulses at 10 Hz for 10 s [32]. Parallel fiber
stimulation was performed throughout the experiment to test the
general physiological condition of the cerebellar cortex. To
SCA8 RNA Gain of Function
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and interneurons), an epoxylite-coated tungsten microelectrode
(,5 M) was placed just into the molecular layer [33].
The basic imaging paradigm consists of collecting a series of 10
control frames (background) followed by a series of 500
experimental frames with an exposure time of 200 ms for each
frame (Metamorph Imaging System, Universal Imaging Corp.).
Whisker pad stimulation was initiated at the onset of the
experimental frames. This was repeated 4 times and the 4 series
were averaged. Each pixel in this series of average images was
converted into the change in fluorescence above background (DF/
F) [32]. The maximal response to whisker stimulation occurred in
frames 31–75 and these frames were averaged to generate the
response image. A pixel was defined as responding to the
peripheral stimulation by the following threshold procedure. First,
the response image was low-pass filtered (363) and the mean and
standard deviation (SD) of the pixels in a control region (usually a
corner of the image) were determined. The pixels above the mean
+ 1 SD of the control region were considered to respond to the
stimulus. The response area was defined as total area of all the
pixels responding and the response intensity as the sum of the DF/
F of all responding pixels. Differences in the area and intensity of
the responses between the SCA8 and FVB mice were evaluated
using a Student’s t-test (a=0.05). For display the pixels above or
below this mean61 SD were pseudo-colored and superimposed on
an image of the folia studied.
Supporting Information
Table S1 Candidate RNA Gain-of-Function Targets by Cross-
Linking and Immunoprecipitation (CLIP).
Found at: doi:10.1371/journal.pgen.1000600.s001 (0.18 MB
XLS)
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